ATE387451T1 - Chinazolinderivate als src- tyrosinkinaseinhibitoren - Google Patents

Chinazolinderivate als src- tyrosinkinaseinhibitoren

Info

Publication number
ATE387451T1
ATE387451T1 AT03769689T AT03769689T ATE387451T1 AT E387451 T1 ATE387451 T1 AT E387451T1 AT 03769689 T AT03769689 T AT 03769689T AT 03769689 T AT03769689 T AT 03769689T AT E387451 T1 ATE387451 T1 AT E387451T1
Authority
AT
Austria
Prior art keywords
tyrosine kinase
kinase inhibitors
quinazoline derivatives
src tyrosine
src
Prior art date
Application number
AT03769689T
Other languages
German (de)
English (en)
Inventor
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE387451T1 publication Critical patent/ATE387451T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03769689T 2002-11-04 2003-10-29 Chinazolinderivate als src- tyrosinkinaseinhibitoren ATE387451T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02292736 2002-11-04
EP03290900 2003-04-10

Publications (1)

Publication Number Publication Date
ATE387451T1 true ATE387451T1 (de) 2008-03-15

Family

ID=32313852

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03769689T ATE387451T1 (de) 2002-11-04 2003-10-29 Chinazolinderivate als src- tyrosinkinaseinhibitoren

Country Status (27)

Country Link
US (1) US7462623B2 (enExample)
EP (1) EP1562955B1 (enExample)
JP (2) JP4593464B2 (enExample)
KR (1) KR101089462B1 (enExample)
AR (1) AR041884A1 (enExample)
AT (1) ATE387451T1 (enExample)
AU (1) AU2003278383B2 (enExample)
BR (1) BR0315756A (enExample)
CA (1) CA2503371C (enExample)
CO (1) CO5560578A2 (enExample)
CY (1) CY1108061T1 (enExample)
DE (1) DE60319410T2 (enExample)
DK (1) DK1562955T3 (enExample)
EG (1) EG24957A (enExample)
ES (1) ES2300619T3 (enExample)
IL (1) IL168013A (enExample)
IS (1) IS2568B (enExample)
MX (1) MXPA05004858A (enExample)
MY (1) MY137835A (enExample)
NO (1) NO331951B1 (enExample)
NZ (1) NZ539408A (enExample)
PL (1) PL215161B1 (enExample)
PT (1) PT1562955E (enExample)
RU (1) RU2350618C2 (enExample)
SI (1) SI1562955T1 (enExample)
TW (1) TWI320786B (enExample)
WO (1) WO2004041829A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0427697D0 (en) 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
DK2387563T4 (da) 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
FI2621481T4 (fi) 2010-09-27 2023-01-13 Met- ja vegf-kaksoisestäjiä kastraatioresistentin eturauhassyövän ja osteoblastisten luun etäispesäkkeiden hoitamiseen
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US20220040181A1 (en) 2018-09-10 2022-02-10 Mirati Therapeutics, Inc. Combination therapies
CN119504612A (zh) * 2024-11-18 2025-02-25 中国海洋大学 一种喹唑啉茋类衍生物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
DK0584222T3 (da) * 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9205320D0 (en) * 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
DE69734149T2 (de) 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivate und verwendung als heilmittel
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CA2263479A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as vegf
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
NZ510551A (en) 1998-09-29 2003-03-28 American Cyanamid Co Substituted 3-cyanoquinolines useful as protein tyrosine kinases inhibitors
DE69925141T2 (de) 1998-10-08 2006-04-27 Astrazeneca Ab Chinazolin derivate
TR200500745T2 (tr) 1999-02-10 2005-05-23 Astrazeneca Ab Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
HUP0204413A3 (en) 1999-09-21 2003-07-28 Astrazeneca Ab Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them
JP3522727B2 (ja) 1999-11-05 2004-04-26 アストラゼネカ アクチボラグ Ｖｅｇｆ阻害剤としてのキナゾリン誘導体
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
DE60121931T2 (de) 2000-04-07 2007-03-01 Astrazeneca Ab Chinazolinverbindungen
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153947A0 (en) 2000-08-09 2003-07-31 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
MXPA03000874A (es) 2000-08-09 2003-06-06 Astrazeneca Ab Compuestos quimicos.
NZ523388A (en) 2000-08-09 2004-09-24 Astrazeneca Ab Cinnoline compounds
BR0113358A (pt) * 2000-08-21 2003-07-01 Astrazeneca Ab Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
WO2002030924A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
WO2002030926A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives
AU2002212436A1 (en) 2000-10-25 2002-05-06 Astrazeneca Ab Quinazoline derivatives
US7141577B2 (en) 2001-04-19 2006-11-28 Astrazeneca Ab Quinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
EP1409481B1 (en) 2001-07-16 2006-10-04 Astrazeneca AB Quinoline derivatives and their use as tyrosine kinase inhibitors
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
WO2003047582A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives as antitumour agents
PL371486A1 (en) 2002-02-01 2005-06-13 Astrazeneca Ab Quinazoline compounds
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
AU2003281193A1 (en) 2002-07-09 2004-01-23 Astrazeneca Ab Quinazoline derivatives for use in the treatment of cancer
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
WO2004014383A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
MXPA05008583A (es) 2003-02-13 2005-11-04 Astrazeneca Ab Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent

Also Published As

Publication number Publication date
PL215161B1 (pl) 2013-10-31
DK1562955T3 (da) 2008-06-02
EG24957A (en) 2011-02-28
AU2003278383B2 (en) 2007-06-14
CA2503371C (en) 2011-01-11
PL376255A1 (en) 2005-12-27
HK1079195A1 (en) 2006-03-31
EP1562955A1 (en) 2005-08-17
CO5560578A2 (es) 2005-09-30
IS7849A (is) 2005-05-19
BR0315756A (pt) 2005-09-06
IL168013A (en) 2013-03-24
NO20051900L (no) 2005-06-01
SI1562955T1 (sl) 2008-06-30
CY1108061T1 (el) 2014-02-12
NO331951B1 (no) 2012-05-14
JP4593464B2 (ja) 2010-12-08
NZ539408A (en) 2007-09-28
KR20050074526A (ko) 2005-07-18
TW200420567A (en) 2004-10-16
WO2004041829A1 (en) 2004-05-21
JP2010270143A (ja) 2010-12-02
MY137835A (en) 2009-03-31
US20060122199A1 (en) 2006-06-08
TWI320786B (en) 2010-02-21
RU2350618C2 (ru) 2009-03-27
EP1562955B1 (en) 2008-02-27
MXPA05004858A (es) 2005-07-22
CA2503371A1 (en) 2004-05-21
JP2006506463A (ja) 2006-02-23
RU2005117337A (ru) 2006-01-20
PT1562955E (pt) 2008-05-05
DE60319410D1 (en) 2008-04-10
ES2300619T3 (es) 2008-06-16
AR041884A1 (es) 2005-06-01
DE60319410T2 (de) 2009-02-19
KR101089462B1 (ko) 2011-12-07
US7462623B2 (en) 2008-12-09
AU2003278383A1 (en) 2004-06-07
IS2568B (is) 2010-01-15

Similar Documents

Publication Publication Date Title
ATE395346T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
IL174258A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
ATE309996T1 (de) Chinolinonderivate als tyrosin-kinase inhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
IS6968A (is) Nýir týrósínkínasa tálmar
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
ATE498613T1 (de) Chinazolinonderivate als parp-hemmer
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
ATE445613T1 (de) Indolylmaleimidderivative als proteinkinase-c- inhibitoren
DE60328735D1 (de) Chinazolinderivate
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
DK1534290T3 (da) Hidtil ukendte kinasehæmmere
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
EP1534268A4 (en) TYROSINE KINASE INHIBITORS
DE602004004553D1 (de) Chinazolinderivate
DE602004022180D1 (de) Chinazolinderivate
AU2003233455A1 (en) Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
ATE387451T1 (de) Chinazolinderivate als src- tyrosinkinaseinhibitoren
IL184798A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1562955

Country of ref document: EP